Traws Pharma (FRA:0T2) Buildings And Improvements : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Buildings And Improvements?

Traws Pharma Buildings And Improvements Historical Data

The historical data trend for Traws Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Buildings And Improvements Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Traws Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Traws Pharma (FRA:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

ONTX:USA

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines